<DOC>
	<DOC>NCT01260194</DOC>
	<brief_summary>This open-label, multi-center study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with standard chemotherapy as first-line treatment in patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Patients will receive standard chemotherapy for a maximum of 6 cycles, and 8 mg/kg Herceptin as loading dose on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression.</brief_summary>
	<brief_title>A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction with advanced or metastatic disease, not amenable to curative therapy Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST) HER2 positive tumor (primary tumor or metastasis ECOG Performance status 0, 1 or 2 Life expectancy of at least 3 months Previous chemotherapy for advanced or metastatic disease less than 6 month before study start Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (patients with partial or total gastrectomy are allowed to participate in the study) Patients with active (significant or uncontrolled) gastrointestinal bleeding Residual relevant toxicity resulting from previous chemotherapy Other malignancy within the last 5 years (except carcinoma in situ of the cervix, or basal cell carcinoma)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>